News
We send the latest information from SMC Laboratories.
STZ: Type 1 or Type 2 Diabetes?
When discussing our unique NASH-HCC model STAM with clients, we are so often asked: What type of diabetes does…
Reserve a non-clinical pharmacology consultation with us at BioPharm America!
We are joining BioPharm America™ Digital, one of the most famous virtual biotech partnering and educatio…
BioJapan – join us!
We will be attending the annual 24th BioJapan from Wednesday, October 13th, 2021 – Friday, October 15th,…
Lung fibrosis in COVID-19
COVID-19 is now being recognized as a multi-organ disease that causes not only pneumonia, but also cause damag…
ENYO Pharma announces positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks
ENYO Pharma (France) announced on 28 July, 2021, positive Vonafexor (EYP001) results for the LIVIFY phase 2a s…
National Defense Medical College's publication in Surgery Open Science
SMC announces that National Defense Medical College (Japan) has published the results of a study using STAM&tr…
The virtual 81st Scientific Sessions of the American Diabetes Association® and updated information on our original NASH-HCC model (STAM™)
We recently made a presentation on our STAM™ mouse at the 81st Annual Meeting of the American Diabe…
Introducing our new model: Liver Orthotopic Xenograft mouse model
We’re getting in touch today with an announcement regarding the addition of the Liver Orthotopic Xenogra…
Our clients’ presentations at DDW 2021
Our clients presented data on treatment of NASH using STAMTM model at the DDW2021 (May 21-23). For deta…
SMC announces Presentation of New Data at the 81st Annual Meeting of the American Diabetes Association
We are pleased to announce the acceptance of our abstract, “RNA-seq Analysis of Liver from Diabetic and …